Description: Reunion (formerly, Field Trip Health Ltd.) is committed to developing innovative therapeutic solutions for mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. The U.S. Patent and Trademark Office has granted the Company a patent for the claims related to RE104, granting it exclusive rights to the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including RE104. The patent will provide protection until 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
Home Page: www.fieldtriphealth.com
REUN Technical Analysis
30 Duncan Street
Toronto,
ON
M5V 2C3
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Hannan Fleiman | Co-Founder & Non-Independent Director |
| Mr. Mujeeb Jafferi | CO-Founder & COO |
| Dr. Nathan Bryson B.Sc., Ph.D. | Chief Scientific Officer |
| Mr. Gregory T. Mayes Esq., J.D. | Pres, CEO & Director |
| Mr. Edward F. Smith CPA | Chief Financial Officer |
| Mr. Matt Emmer | Director of Operations & Bus. Devel. |
| Curtis Weber | Gen. Counsel & Corp. Sec. |
| Mr. Stephan Cote | Head of Quality |
| Ms. Vicki Reed | Chief Growth Officer |
| Dr. Michael Verbora M.B.A., M.D. | Sr. VP & Medical Director |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4872 |
| Price-to-Sales TTM: | 3.7615 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 194 |